ELUVIA™ Benefits Patients and Hospitals
Combining unprecedented clinical results with proven patient outcomes, the Eluvia Drug-Eluting Vascular Stent System allows your hospital to achieve strong procedural economics and enhance operational efficiencies.
A Proven Treatment for PAD
Unprecedented Clinical Results
Eluvia has demonstrated superior results in the first head-to-head superficial femoral artery (SFA) clinical trial. In fact, data from the IMPERIAL Trial show that Eluvia provides a statistically significant difference in primary patency compared to Zilver™ PTX™ at 12 months.
IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication.
Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0144).
"The Eluvia stent is a breakthrough therapy that marks a significant step forward in the treatment of peripheral artery disease. And now with its approval and commercial availability, it has the potential to make an immediate impact on the quality and value of care that physicians can provide to their patients."
William Gray, MD
Prin. Investigator, IMPERIAL Trial
Lankenau Heart Institute/Main Line Health
Improved Patient Outcomes and Satisfaction
- Eluvia demonstrated half the TLR rate of Zilver PTX at 12 months, which could mean fewer reinterventions and visits to the hospital
- 91% of patients had no or minimal pain with walking at 2 years3
- 89.6% of patients improved by at least one Rutherford category without the need for TLR
Delivers Operational Efficiencies and Strong Economic Value
With Eluvia, you can provide a proven PAD treatment while enhancing operational efficiencies and achieving your hospital’s financial goals.
Eluvia Simplifies Procedures and
Reduces Procedural Time
The Eluvia Drug-Eluting Stent
- May simplify the procedure, reduce procedure time and allow for better resource utilization
- Offers highly favorable reimbursement compared to drug-coated balloons (DCB) and Fempop bypass surgery
- May help reduce costs associated with reinterventions and hospital readmissions
"The fact that the IMPERIAL trial demonstrated 50% reduction in target lesion revascularization, this is a tremendous amount of benefit to our patients."
Robert Lookstein, MD
Mount Sinai Medical Center
New York, NY
PAD Fact Sheet
Get the facts about PAD, including risk factors, signs and symptoms, treatment options and more.
IMPERIAL Data Sheet
See the remarkable results the Eluvia Drug-Eluting Stent achieved in this first head-to-head trial comparing Eluvia DES vs. Zilver PTX.
ELUVIA Economic Value Presentation
Learn more about PAD and critical limb ischemia (CLI), the evolution of treatments for these conditions, and how Eluvia can help you deliver durable patient outcomes and economic value.
A Physician’s Perspective on Eluvia
Hear Dr. Lookstein’s perspective on the IMPERIAL Trial results and the clinical and financial benefits of Eluvia.
FemPop Reimbursement and Coding Guide
Find hospital inpatient and outpatient, ambulatory surgical center, physician service and OBL reimbursement information for femoral/popliteal procedures.
Leg Pain Reduction Chart
Download a chart showing that 89.6% of Eluvia patients had improvement by at least one Rutherford category compared with baseline without the need for TLR.
Stay Up to Date
Sign up to receive emails about clinical results and how Eluvia can help you improve patient outcomes and enhance operational efficiencies.